指南与共识肝病

非酒精性脂肪性肝病风险分层与管理的临床照护路径

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
指南 / 共识 · Gastroenterology · 2021-09-20

美国胃肠病协会组织多学科专家组制定非酒精性脂肪性肝病(NAFLD)临床照护路径,针对约37%美国成人患病的现状,提供筛查、诊断和治疗的具体指导,重点识别临床显著纤维化(F2-F4期)患者,适用于基层、内分泌、肥胖医学和消化科等场景。

要点

  • NAFLD影响约37%美国成人,多在基层或内分泌科管理。
  • 路径指导筛查、诊断和治疗,重点识别F2-F4期纤维化患者。
  • 适用于基层、内分泌、肥胖医学和消化科等诊疗场景。

核心结论

  • 美国胃肠病协会多学科专家组制定NAFLD临床照护路径,为筛查、诊断和治疗提供明确指导。

研究设计与样本

  • 美国胃肠病协会组建多学科专家组制定临床照护路径,基于最佳可用证据提出建议。

主要发现

  • NAFLD目前影响约37%的美国成人,且通常无症状。
  • NAFLD多在基层或内分泌科管理,需判断患者是否需转诊二级 care。
  • 优化治疗时机取决于准确的纤维化风险分期。

关键数值与推荐

  • 路径重点针对临床显著纤维化(F2-F4期)患者的诊断和管理提出步骤。

临床怎么用

  • 路径适用于基层、内分泌、肥胖医学和消化科等提供NAFLD照护的任何场景。
  • 基层筛查需结合一致的、及时的、循证的、广泛可及且可测试的管理流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.gastro.org. Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common, currently affecting approximately 37% of US adults. NAFLD is most often managed in primary care or endocrine clinics, where clinicians must determine which patients might benefit from secondary care to address hepatic manifestations, comorbid metabolic traits, and cardiovascular risks of the disease. Because NAFLD is largely asymptomatic, and because optimal timing of treatment depends on accurate staging of fibrosis risk, screening at the primary care level is critical, together with consistent, timely, evidence-based, widely accessible, and testable management processes. To achieve these goals, the American Gastroenterological Association assembled a multidisciplinary panel of experts to develop a Clinical Care Pathway providing explicit guidance on the screening, diagnosis, and treatment of NAFLD. This article describes the NAFLD Clinical Care Pathway they developed and provides a rationale supporting proposed steps to assist clinicians in diagnosing and managing NAFLD with clinically significant fibrosis (stage F2-F4) based on the best available evidence. This Pathway is intended to be applicable in any setting where care for patients with NAFLD is provided, including primary care, endocrine, obesity medicine, and gastroenterology practices.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kanwal F, Shubrook JH, Adams LA, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2021. PMID: 34602251. doi:10.1053/j.gastro.2021.07.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。